Lilly Preparing For Increasing Mounjaro Demand On Top Of Solid Launch

The pharma is increasing its manufacturing capacity for tirzepatide, mindful of its potential in a second indication of obesity and the supply issues faced by competitor Novo Nordisk.

Eli Lilly logo sign atop Lilly Biotechnology Center campus of an American pharmaceutical company Eli Lilly and Company
Tirzepatide may soon compete with semaglutide in two major indications • Source: Shutterstock

Launch metrics for Eli Lilly and Company’s GIP/GLP-1 analog Mounjaro (tirzepatide) in type 2 diabetes are exceeding expectations to this point, and the pharma reported during its 1 November earnings call that commercial coverage in the US increased significantly during the third quarter. Perhaps mindful of the supply issues faced by competitor Novo Nordisk A/S with Ozempic/Wegovy (semaglutide), Lilly is trying to prepare for high demand for the product in two major indications ahead of the planned submission for obesity in 2023.

[Sidebar#SC146825]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.